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Abstract 
A ubenimex-sensitive aminopeptidase B-like enzyme was purified from the non-membrane-bound fraction of K562 cells by a series of chromato- 
graphic procedures and slab-gel electrophoresis. The apparent molecular mass of the enzyme was estimated to be 73 kDa by SDS-PAGE. The 
aminopeptidase activity was activated by chloride ions and inhibited by Zn*+, Cu*+, Cd*‘, and p-chloromercuribenzoic a id. Ubenimex was a potent 
inhibitor of this aminopeptidase in the nanomolar range. The sequence of the N-terminus of the protein was not determined. Partial amino acid 
sequencing revealed that the N-terminus of this aminopeptidase B-like enzyme was blocked by acylation. The partial sequences of the two fragments 
produced by CNBr cleavage and an acylamino acid-releasing reaction showed this enzyme to be a new aminopeptidase. 
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1. Introduction 
Aminopeptidase B (APase B; EC 3.4.11.6), an exopep- 
tidase widely distributed in mammalian tissues, catalyzes 
the hydrolysis of arginyl and lysyl residues from the 
amino-terminus of polypeptide chains [l-4]. Although 
APase B was first purified from rat liver in 1966 [5], the 
physiological functions of this enzyme have yet to be 
elucidated. In our laboratory, the presence of a ubeni- 
mex-sensitive APase B-like enzyme was indicated by the 
fact that ubenimex inhibited proliferation of K562 
human chronic myeloid leukemia cells. Ubenimex, a 
dipeptide found in the culture filtrate of Streptomyces 
olivoreticuli, is a potent inhibitor of aminopeptidase N 
(APase N) and APase B [6]. Recently, it was shown that 
the myeloid cell surface glycoprotein, CD13, was identi- 
cal to APase N [7], and that APase N limited neutrophili 
inflammatory responses and promoted monocyte anti- 
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Abbreviations: AMC, 7-amino-4-methyl-coumarin; AUF& absorbance 
unit full scale; CD, cluster of differentiation; CNBr, cyanogen bromide; 
DMSO, dimethyl slufoxide; EDTA, ethylenediaminetetraacetic acid; 
EGTA, ethylene glycol bis @-aminoethylether)-N,N,N’,N’,-tetra acetic 
acid; kDa, kilodaltons; MCA, 4-methylcomnaryl-7-amide; PCMB, p- 
chloromercuribenzoic acid; PMSF, phenyhnethylsulfonyl fluoride; 
PTH, phenylthiohydantoin; SDS-PAGE, sodium dodecyl poly- 
acrylamide gel electrophoresis; TFA, trifluoroacetic acid. 
Ubenimex (Bestatin) and leupeptin were prepared by Nippon Kaya- 
ku Co. AMC, Arg-MCA, Leu-MCA, Ala-MCA, Phe-MCA, E-64, and 
antipain were purchased from The Peptide Institute. Mono Q and 
EAH-Sepharose were from Pharmacia Fine Chemicals. Biotine HIC- 
PH was from Japan Spectroscopic Co. Immobilon-P was from Mil- 
lipore Co. Acylamino acid-releasing enzyme was from Takara Shuzo 
Co. Trypsin (sequencing rade) was from Boehringer-Mannheim Bio- 
chemica. Isolated peptides were sequenced using an Applied Biosystems 
model 470A Protein Sequencer equipped with a model 120A on-line 
PTH analyzer. 
gen processing [8]. Previous studies have revealed that 
ubenimex has immunomodulatory [9-121 and host-medi- 
ated anti-tumor activities [ 131. 
These results suggest hat immunomodulatory activi- 
ties are related to cell surface aminopeptidases [14]. 
However, the proliferation of K562 cells was inhibited 
by ubenimex and arphamenin B, a potent inhibitor of 
APase B, but not by an anti-CD1 3 monoclonal antibody. 
Further, ubenimex effectively inhibited APase B. There- 
fore, a ubenimex-sensitive APase B-like enzyme in K562 
cells was speculated to act for APase N of other myeloid 
cells, because expression of APase N was very low in 
K562 cells [15]. 
In this report, we describe the purification and partial 
amino acid sequencing of a ubenimex-sensitive APase 
B-like enzyme from the non-membrane-bound fraction 
of K562 cells. 
2. Materials and methods 
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2.2. Cells 
K562 cells were maintained in RPM11640 medium supplemented 
with 10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 100 
&ml streptomycin, and 100 U/ml penicillin in a humidified 5% CO, 
atmosphere at 37°C. 
AMC. Results were expressed as nM of AMC formed per 1 min at 
37°C. For the inhibition experiments, Ca’+- and Mg”-free PBS was 
used instead of Hanks’ solution. 
2.6. Protein sequencing 
2.3. Preparing Ubenimex-Sepharose 4B 
Ubenimex-Sepharose 4B was prepared essentially according to the 
method described in the brochure issued by Pharmacia Fine Chemicals. 
In brief, 297 mg of ubenimex was coupled with 25 ml of EAH-Sepha- 
rose 4B. Binding of bestatin to Sepharose was checked by inhibition of 
leucine aminopeptidase hydrolytic activity. 
2.4. Enzyme purification 
The following steps were all performed at 4°C. K562 cells (1.1 x lo9 
cells) were homogenized with 40 ml of 20 mM sodium acetate buffer, 
pH 6.0, containing 50pM leupeptin, 50pM antipain, 2 mM PMSF, and 
1 mM /Lmercaptoethanol in a Teflon homogenizer. The homogenates 
were centrifuged at 20,000 x g for 30 min. The supematant was adjusted 
to pH 6.0 and applied to a ubenimex-Sepharose 4B column (diam. 
10 x 113 mm), equilibrated with 20 mM sodium acetate buffer, pH 6.0. 
The column was washed with the same buffer until the absorbance of 
the eluate at 280 nm had reached 0.05 AUFS. The enzyme was then 
eluted with a linear gradient of tL0.5 M NaCl in 20 mM sodium acetate 
buffer, pH 6.0. Aminopeptidase activity was assayed by measuring 
AMC liberated from amino acid-MCA after incubation. The solution 
was incubated at 37°C in 20 mM Tris-HCl buffer, pH 7.2 (total 200 ~1) 
containing 0.1 mM amino acid-MCA. The liberated AMC was meas- 
ured fluorometrically with a Fluorescence Concentration Analyzer 
(Baxter). The active fractions that eluted at about 0.23 M NaCl were 
pooled and dialyzed against 20 mM Tris-HCl buffer, pH 8.0, containing 
1 mM /I-mercaptoethanol for 12 h. The dialyzed fraction was applied 
to a Mono Q column (diam. 5 x 50 mm) equilibrated with 20 mM 
Tris-HCl buffer, pH 8.0, and was eluted with a linear gradient of O-O.5 
M NaCl. The active fractions were eluted about 0.17 M NaCl. The 
enzyme solution was adjusted to 0.5 M NaCl and 20% ammonium 
sulfate, and centrifuged at 15,000 x g for 20 min. The supematant was 
applied to a Biofine HIC-PH column (diam. 7.5 x 75 mm), equilibrated 
with 20 mM Tris-HCl, pH 8.0, containing 20% ammonium sulfate. The 
enzyme was eluted at about 4% ammonium sulfate, and was dialyzed 
against 20 mM Tris-HCl buffer, pH 7.5 (Table 1). To remove contam- 
inants, a slab gel electrophoresis was performed. The enzyme fraction 
was applied to a slab gel and a voltage of 300 V was run for 2.5 h at 
4°C. A 2 mm-wide section of the gel was cut out and was crushed in 
20 mM Tris-HCl, pH 7.5. After centrifugation at 10,000 x g for 10 min, 
the supematant was collected and assayed. The enzyme fractions, which 
hydrolyzed Arg-MCA and migrated as a single protein band on SDS- 
PAGE under reducing conditions (Fig. l), were used for amino acid 
sequencing. 
The purified enzyme fraction was subjected to SDS-PAGE (12.5% 
polyacrylamide) and separated proteins were electrophoretically trans- 
ferred to Immobilon-P. The ubenimex-sensitive APase B-like enzyme 
on Immobilon-P was carefully cut out and subjected to amino-terminal 
sequence analysis. Several enzyme fragments were generated by limited 
CNBr proteolysis of the protein on the membrane [16]. Deblocking and 
subsequent sequence analysis were performed according to the method 
of Hirano et al. [17]. The enzyme on a membrane was digested with 
trypsin treated with phenylisothiocyanate, following addition of per- 
formic acid to convert the N-terminal phenylthiocarbamyl groups of 
the peptides to phenylcarbamyl groups by oxidation. The acylamino 
acid-releasing enzyme (81 pug/ml) was added to the peptide mixture to 
remove the N-acylated amino acids. 
3. Results and discussion 
3.1. Pur$cation of a ubenimex-sensitive APase B-like 
enzyme from the non-membrane-bound fraction of 
K562 cells 
Leu-, Ala-, Arg-, and Phe-MCA hydrolytic activities 
were examined for membrane and non-membrane bound 
fractions of K562 cells. The non-membrane-bound frac- 
tion had 50- to 140-fold higher activity than the mem- 
brane fraction (data not shown). Furthermore, Arg- 
MCA hydrolytic activity was the highest among the 
substrates tested and was inhibited by ubenimex most 
efficiently. 
2.5. Aminopeptidase assay 
Aminopeptidase activity was assayed by measuring AMC liberated 
from amino acid-MCA after incubation. The enzyme solution was 
incubated for 1 h at 37°C in a Hanks’ solution (total, 200~1) containing 
0.1 mM amino acid-MCA dissolved in DMSO. The 6nal concentration 
of DMSO was 1%. Each reaction was terminated by addition of 100 
mM EDTA (50~1). The liberated AMC was measured fluorometrically 
with a Fluorescence Concentration Analyzer (Baxter). Aminopeptidase 
activity was quantified by reference to a standard curve prepared with 
We tried to purify the ubenimex-sensitive aminopepti- 
dase by monitoring Arg-MCa hydrolytic activity. The 
enzyme exhibited both affinity- and ionic-exchange inter- 
actions on a ubenimex-Sepharose column and a Biofine 
HIC-PH hydrophobic chromatography procedure was 
also successfully used (Table 1). The aminopeptidase 
fraction eluted was examined by SDS-PAGE (Fig. 1A). 
Due to the existence of several extraneous protein bands, 
we used gel-electrophoresis and eluted the 73 kDa pro- 
tein with Arg-MCA hydrolytic activity. Finally, the en- 
zyme was purified as a single band of 73 kDa on SDS- 
PAGE (Fig. 1B). Because the molecular weight of this 
enzyme was identical on SDS-PAGE under both reduc- 
ing and non-reducing conditions, it was likely that the 
ubenimex-sensitive APase B-like enzyme was a single 
polypeptide. This molecular weight is similar to a 72 kDa 
Table 1 
Purification of ubenimex-sensitive APase B-like enzyme from K562 cells 
Purification step Total volume Total protein Activity Specific activity Recovery 
(ml) (mg) (nmol/min) (nmol/min/mg) (%) 
Crude extract 42 76.4 1,197 15.7 100 
Ubenimex-Sepharose 8.0 6.05 851 140.7 71 
Mono Q 4.5 0.639 229 358.4 19 
Biofine HIC-PH 3.8 0.0067 14.5 2,164.2 1.2 
“Hydrolyzing activity of Arg-MCA. 
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Fig. 1. SDS-PAGE of ubenimex-sensitive APase B-like enzyme. (A) 
SDS-PAGE of Biofine fraction: left lane, molecular weight marker; 
right lane, Biofine fraction. (B) SDS-PAGE of active fraction of gel- 
electrophoresis performed according to the method of Davis [20]: left 
lane, molecular weight marker; right lane, active fraction. 
APase B from the cytosol of Jurkat T cells [18]. For 
characterization of the enzyme, we used the enzyme solu- 
tion hydrophobic chromatography step. The same prep- 
aration was also subjected to SDS-PAGE, then trans- 
ferred to a PVDF membrane and was used for amino 
acid sequencing. 
3.2. Characterization of enzyme 
In the synthetic substrates tested, Arg-MCA was the 
best substrate and Lys-MCA hydrolytic activity was 75% 
of Arg-MCa, Leu-, Ala-, Phe-, and Met-MCA were not 
hydrolyzed. The results show that the purified enzyme 
preferentially hydrolyzes basic amino acid-MCA sub- 
strates. The optimal pH of the enzyme activity was pH 
7.0 (data not shown). Table 2 shows the effects of various 
affecters on the enzyme. Sodium chloride at a concentra- 
tion of 50 mM increased the hydrolytic activity of Arg- 
MCA up to 170%, but PCMB and heavy metal ions 
Table 2 
Effect of various affecters on ubenimex-sensitive APase B-like enzyme 
Affecters 
cl- 
PCMB 
Zn2+ 
CU2’ 
Cd*+ 
o-Phenanthroline 
EDTA 
EGTA 
Benxamidine 
PMSF 
E-64 
Bestatin 
Concentration 
(mM) 
50 
0.1 
0.1 
0.1 
0.1 
0.1 
1.0 
1.0 
1.0 
1.0 
0.01 
0.001 
(ICsO 38 nM) 
Relative activity 
(%) 
170.3 
0.93 
1.43 
0.0 
5.95 
44.20 
107.72 
103.32 
84.57 
70.48 
94.23 
0.0 
Table 3 
Sequence of ubenimex-sensitive APase B-like enzyme 
N-Terminal fragment 
CNBr treatment fragment 
Acyl-xxIILNQWxN 
xNxFEAYFK 
x denotes unidentified amino acid residue. 
markedly inhibited the activity. These properties are sim- 
ilar to APase B from other sources reported [l-5]. Ben- 
zamidine and PMSF, inhibitors of serine proteases, had 
little inhibitory effect on the enzyme. l,lO-Phenanthro- 
line, a metal-chelating agent, exhibited 65% inhibition at 
a concentration of 0.1 mM, whereas EDTA and EGTA 
had no effect up to 1.0 mM. Since exo-type metallopro- 
teases are inhibited by EDTA and EGTA [19], this en- 
zyme may be a member of exo-type metalloprotease. Of 
the inhibitors tested, ubenimex is the strongest inhibitor 
for the purified enzyme with an ICso value of 38 nM. 
E-64, an inhibitor of cysteine protease, did no inhibit the 
APase N or B activity. These results showed that the 
purified enzyme is a metalloprotease xhibiting identical 
properties to APase B. 
3.3. Protein sequencing 
The N-terminal amino acid sequence of the APase 
B-like enzyme was analyzed after transfer on to an Im- 
mobilon-P membrane. However, no signals were de- 
tected, suggesting that the N-terminus of the enzyme is 
blocked. Treatment with 0.6 N HCl or with vapor phase 
TFA was not succesful, indicating that the N-terminus 
is neither modified by formylation nor was it an acetyl- 
serine or acetyl-threonine. The APase B-like enzyme with 
acylamino acid-releasing enzyme deblocked the N-termi- 
nus of the enzyme. The first amino acid signal could not 
be identified because of amino acid contamination, but 
the sequence from the second amino acid signal was 
determined (Table 3). The peptide fragment that was 
generated from the whole protein by CNBr treatment 
was sequenced, and the result is also shown in Table 3. 
Homology searches were performed for two partial se- 
quences with the data-bases NBRF-PIR (R37.0) and 
SWISS-PROT (R25.0). However, the sequences did not 
correspond to any proteins in these data-bases. Thus, at 
present, this ubenimex-sensitive APase B-like enzyme is 
expected to be a new aminopeptidase. 
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